TB-500 + Sermorelin Stack: Complete Protocol, Dosing, and Safety Guide

What Are These Two Peptides and Why Stack Them?

TB-500 and Sermorelin address recovery from different angles. TB-500 acts locally and systemically to repair damaged tissue, while Sermorelin works through the hypothalamic-pituitary axis to restore a physiologic GH pulse. The rationale for combining them is that GH-driven anabolic signaling may amplify the tissue-repair environment that TB-500 creates, though this combination is inferred from mechanism rather than confirmed in controlled trials.

TB-500: Mechanism and Evidence Base

Thymosin beta-4 (Tβ4) is a 43-amino-acid peptide expressed in virtually all human cells. Its primary role is sequestering actin monomers, which regulates cell migration, wound healing, and inflammatory signaling. TB-500 refers to the synthesized active fragment corresponding to the actin-binding domain.

Animal studies support its regenerative properties. A 2010 study published in the Journal of Molecular and Cellular Cardiology found that Tβ4 administration after myocardial infarction in rodents reduced infarct size and improved left ventricular function by promoting cardiomyocyte survival and angiogenesis (pubmed.ncbi.nlm.nih.gov/19804772). Tβ4 also accelerated dermal wound closure in a controlled murine model, with treated wounds closing roughly 42% faster than controls (pubmed.ncbi.nlm.nih.gov/10400766).

Human RCT data for TB-500 remains scarce. A phase 2 trial (NCT01311518) investigated Tβ4 in epidermolysis bullosa and demonstrated acceptable tolerability, but the trial was not powered for efficacy endpoints (pubmed.ncbi.nlm.nih.gov/25654336).

Sermorelin: Mechanism and Regulatory History

Sermorelin acetate is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-29). Binding to the pituitary GHRH receptor triggers GH secretion in a pulsatile, physiologic pattern, preserving the normal feedback loop through somatostatin. This distinguishes it from exogenous recombinant GH, which bypasses pituitary regulation entirely.

The FDA approved Sermorelin (Geref) in 1997 for growth hormone deficiency in children. The NDA holder voluntarily withdrew the product from the US market in 2008 for commercial reasons, not safety concerns, according to FDA records (accessdata.fda.gov). Compounded sermorelin has since been widely used off-label in adults for GH optimization, though the FDA's 2023 guidance placed certain compounded peptides under increased scrutiny (fda.gov).

A 1997 study in the Journal of Clinical Endocrinology and Metabolism confirmed that 6 months of nightly sermorelin in GH-deficient adults increased mean IGF-1 by 88 mcg/L and improved body composition compared with placebo (pubmed.ncbi.nlm.nih.gov/9284717).

Does Stacking TB-500 With Sermorelin Make Mechanistic Sense?

The two agents target different receptor systems and produce complementary downstream effects. TB-500 reduces nuclear factor-kappa B (NF-kB) activity, lowering pro-inflammatory cytokine output. Sermorelin elevates IGF-1, which itself has documented anti-inflammatory and anabolic properties.

Complementary Pathways

IGF-1 promotes satellite cell activation and protein synthesis through the PI3K/Akt/mTOR axis (pubmed.ncbi.nlm.nih.gov/12869544). TB-500 independently stimulates angiogenesis through upregulation of vascular endothelial growth factor (VEGF) and promotes re-epithelialization. When tissue is healing from injury, increased vascularity combined with elevated IGF-1 could accelerate the repair cycle. The word "could" is appropriate here because no published trial has measured this combination's additive effect in humans.

Evidence Grade for the Stack Itself

No randomized controlled trial or observational cohort study has examined TB-500 and Sermorelin together. The stack rationale is constructed from:

1. Independent preclinical data for each peptide
2. Mechanistic plausibility based on complementary pathways
3. Practitioner-reported outcomes in off-label clinical settings

Practitioners and patients considering this stack should treat it as an investigational protocol, not a standard of care. The American Association of Clinical Endocrinology notes that growth-hormone-stimulating therapies outside approved indications require careful risk-benefit analysis and monitoring (aace.com).

Complete Dosing Protocol

The dosing ranges below reflect published pharmacokinetic data for each peptide individually, adjusted for concurrent use based on practitioner consensus in clinical peptide programs. They do not come from a combination-therapy trial.

TB-500 Dosing

Loading phase (weeks 1 to 6): 4 mg subcutaneous or intramuscular, twice weekly. Some protocols use 8 mg twice weekly for the first two weeks in high-demand scenarios such as acute tendon injury, though higher doses carry greater angiogenic risk.

Maintenance phase (weeks 7 onward): 2 to 2.5 mg twice weekly, or 2 mg once weekly if the loading phase resolved the target complaint.

Injection site: Subcutaneous administration into abdominal fat or thigh is standard. TB-500 is water-reconstituted with bacteriostatic water and stored refrigerated after reconstitution.

Thymosin beta-4 has a short plasma half-life estimated at approximately 30 minutes in animal models, though tissue distribution and effect duration extend well beyond peak plasma concentration (pubmed.ncbi.nlm.nih.gov/22367817).

Sermorelin Dosing

Standard dose: 100 to 300 mcg subcutaneous, administered at bedtime to align with the dominant nocturnal GH pulse.

Frequency: 5 days on, 2 days off. Daily continuous dosing risks pituitary desensitization to GHRH stimulation over time. A 2003 review in Growth Hormone and IGF Research confirmed that intermittent GHRH stimulation preserves pituitary responsiveness better than continuous infusion (pubmed.ncbi.nlm.nih.gov/12914912).

Cycle length: 3 to 6 months, followed by a 4 to 8 week off-period. IGF-1 should be checked at the end of month 2 to confirm response before extending the cycle.

Timing the Two Peptides Together

TB-500 and Sermorelin do not share an administration window. TB-500 injections are typically twice-weekly events on fixed days (e.g., Monday and Thursday). Sermorelin is injected nightly at bedtime. There is no pharmacokinetic reason to space them apart within the same day, since their receptor targets are entirely different. Preparing separate syringes for each is still recommended; combining them in one syringe risks pH incompatibility and has not been tested for stability.

Sample 8-Week Stack Schedule

| Week | TB-500 Dose | Frequency | Sermorelin Dose | Frequency | |------|-------------|-----------|-----------------|-----------| | 1-2 | 8 mg | 2x/week | 200 mcg | 5 on / 2 off | | 3-6 | 4 mg | 2x/week | 200 mcg | 5 on / 2 off | | 7-12 | 2 mg | 2x/week | 200 mcg | 5 on / 2 off | | 13-16 | 2 mg | 1x/week (taper) | 100 mcg | 5 on / 2 off | | 17-20 | Off |, | Off |, |

This schedule reflects a common practitioner framework. Individual adjustments depend on IGF-1 response, symptom resolution, and tolerance.

Who Is a Candidate for This Stack?

The most commonly cited use cases include soft-tissue injury recovery, chronic tendinopathy, post-surgical healing support, and age-related GH decline. Adults with confirmed low-normal IGF-1 (below 150 ng/mL on a standard reference range of 100 to 300 ng/mL for adults aged 30 to 50) who are also managing musculoskeletal injury represent the theoretical sweet spot for this combination.

Candidates should not have:

• Active or suspected malignancy. Both Tβ4 and IGF-1 elevation have documented pro-angiogenic and potentially pro-proliferative effects in cancer cell lines (pubmed.ncbi.nlm.nih.gov/16467833).
• Uncontrolled diabetes. Sermorelin-driven IGF-1 elevation may worsen insulin resistance in poorly controlled type 2 diabetes (pubmed.ncbi.nlm.nih.gov/10232691).
• Acromegaly or a history of pituitary adenoma.
• Pregnancy or active breastfeeding.

Monitoring and Lab Work

Baseline labs before starting the stack should include IGF-1, fasting insulin and glucose, HbA1c, CBC with differential, and a comprehensive metabolic panel. Recheck IGF-1 and fasting glucose at 8 weeks. If IGF-1 rises above the upper limit of the age-adjusted reference range (typically 250 to 350 ng/mL depending on the laboratory), reduce or pause sermorelin.

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults states: "Serum IGF-1 concentrations should be maintained in the age- and sex-specific normal range during GH therapy," a principle that applies equally to GHRH-based therapy (academic.oup.com/jcem).

Liver enzymes (AST, ALT) are worth monitoring quarterly given that both peptides influence cellular proliferation pathways, though hepatotoxicity has not been a reported signal for either agent in available literature.

Side Effects and Risk Profile

TB-500 Side Effects

Reported side effects in available clinical data and practitioner reports are mild. Headache and transient fatigue in the first 48 hours after injection are the most commonly cited reactions. Injection site redness occurs in a minority of users. The main theoretical concern is pro-angiogenic activity in the presence of occult tumor vasculature (pubmed.ncbi.nlm.nih.gov/19804772).

Sermorelin Side Effects

A 1994 study of sermorelin in 89 adults documented the following: injection site pain (17% of subjects), flushing (5%), and headache (4%), all of which resolved without intervention (pubmed.ncbi.nlm.nih.gov/7962297). Antibody formation to sermorelin was reported in a minority of long-term users in early trials, though clinical significance was uncertain.

Water retention is possible with any GH-axis therapy. Carpal tunnel symptoms are a known class effect of GH and GH-stimulating agents, typically dose-dependent and reversible on dose reduction (pubmed.ncbi.nlm.nih.gov/10232691).

Stacking-Specific Risk Considerations

Running both agents simultaneously means two simultaneous pro-growth signals. The combination may be particularly risky in individuals with metabolic syndrome or pre-diabetes, where GH-axis activation is already dysregulated. A fasting glucose above 100 mg/dL at baseline should prompt discussion with a prescribing physician before starting Sermorelin. TB-500's angiogenic upregulation of VEGF, combined with IGF-1's proliferative signaling, may theoretically accelerate undetected lesion growth, though no clinical case series has documented this outcome.

Regulatory and Legal Status

TB-500 is not FDA-approved for human use in any indication. It is sold legally as a research chemical in the United States, with the understanding that it is not for human consumption. Using it without physician oversight bypasses important safety checkpoints.

Sermorelin was FDA-approved but is currently only available through compounding pharmacies operating under 503A or 503B designations. In 2023, the FDA proposed reclassifying several compounded peptides, and practitioners should confirm the current compounding status of sermorelin with their pharmacy before prescribing (fda.gov).

Patients purchasing either peptide from unregulated online sources face risks of underdosing, contamination, and incorrect formulation. A 2018 study analyzing commercial peptide products found that 44 of 44 samples contained detectable peptide, but 25% had concentrations outside the labeled specification by more than 10% (pubmed.ncbi.nlm.nih.gov/29490877).

What the Evidence Does Not Yet Tell Us

The honest answer is that no published study has measured what happens when TB-500 and Sermorelin are combined in humans over 8 to 20 weeks. The available data allows a mechanistically coherent protocol to be constructed, and individual peptide safety profiles are reasonably characterized. The additive or interactive effects on IGF-1, inflammatory markers, or tissue repair speed remain unmeasured.

Practitioners at HealthRX who supervise this stack use IGF-1 response at week 8 as the primary efficacy signal. If IGF-1 remains below 150 ng/mL after 8 weeks of sermorelin at 200 mcg nightly, the pituitary response may be blunted and the dose or timing should be reassessed. Confirmed IGF-1 response in the 180 to 250 ng/mL range suggests the GH-axis component is working.

TB-500 progress is harder to measure biochemically. Practitioners typically rely on subjective pain and functional recovery scores (e.g., a 0-to-10 pain visual analogue scale) at weekly intervals, targeting a 30% or greater reduction in injury-site pain by week 6 as a meaningful response threshold.